Newsletter Signup x

UK Acute Lymphoblastic Leukaemia trial 2011 (UKALL 2011)

This national clinical trial for children with acute lymphoblastic leukaemia builds on the success of the previous trial, UKALL 2003, which pioneered a new molecular technique to stratify children into different treatment groups according to residual levels of leukaemic cells. This new trial will use the technique to monitor the effect of changes to the treatment regime in an attempt to save even more children.

scientist hands

Project Details

  • Project Title

    The genetics of familial leukaemia

  • Lead Researcher

    Dr Pamela Kearns & Dr Nicholas Goulden

  • Research Centre

    University of Birmingham

  • City & Institution Postcode

    Birmingham, B15 2TT

  • Start Date

    28 January 2010

  • Duration

    7 years

  • Grant Amount

    £750,000

Background – clinical trials and leukaemia treatment

Clinical trials help us to find better ways of treating diseases. They allow us to test new treatments and ways of controlling symptoms.

Thanks to the ongoing series of childhood leukaemia trials, huge progress has been made in treating a disease which was almost universally fatal only 50 years ago.

The trials have enabled doctors to develop and refine treatment protocols for children with different types of leukaemia and different risk factors. This has driven up the survival rate to more than 80%.

Most children being treated for leukaemia in the UK will be given the opportunity to take part in a clinical trial. All families have the right to choose whether or not to take part – those who decline will receive the current standard treatment.

UKALL 2011

The aim of the new trial is to take survival even higher. It will build on the success of UKALL 2003, using the MRD test to routinely select treatment for children who are deemed either good or poor risk. Their treatment can be reduced or intensified but still achieve cure.

The MRD test will be used to monitor the effectiveness of an important change to the chemotherapy regime for children with ALL.

Doctors will use a drug called dexamethasone at a much earlier stage in treatment. Evidence suggests that this will reduce the number of children who relapse on treatment.

For more information on clinical trials and childhood cancer, see ‘A Guide to Clinical Trials’ published by the Childhood Cancer and Leukaemia Group.

Results of UKALL 2003

The previous childhood ALL trial, UKALL 2003, closed in March 2010 after six years.

As part of UKALL 2003, doctors pioneered a new technique known as minimal residual disease (MRD) testing to determine how well children were responding to treatment and to predict how likely they were to relapse.

This enabled them to tailor each child’s treatment – so that only children at high risk of relapse were given the most intensive treatment. Since the treatments used for leukaemia carry the risk of some serious side effects, it is important that children are not given more treatment than they need.

MRD testing now takes place routinely during the treatment of children with ALL, with the costs now borne by the NHS. It is thought that this innovation will push the survival rate above 90%.

And, importantly, it will also protect children with lower risk leukaemia from the harmful side-effects associated with high doses of chemotherapy.

About the Research Team

Dr Pamela Kearns & Dr Nicholas Goulden

Newsletter icon

Know someone who might be interested in this article?

Email this page to a friend!
Related research- Dr Helen Bryant

Developing new treatments for high-risk neuroblastoma

Neuroblastoma has a ‘high-risk’ form which, despite using every treatment available, means that some children can’t be cured. ...

Read more
Related research- Dr Suzanne Turner

Learning why high-risk neuroblastoma resists treatment – to learn how to beat it

One of the hardest things about finding a cure for cancer is that many forms don’t respond well ...

Read more
Fundraise for us today!

We've got lots of fun events to choose from!

Read more